BioInvent International (BINV) Q3 2025 earnings summary

Executive summary

• Strategic portfolio refocus prioritized BI-1808 and BI-1206, both in Phase II trials for liquid and solid tumors, with early-stage programs paused and BT-001 continuing in investigator-led studies.

• Board changes included Vincent Ossipow stepping down after nearly 10 years.

• Initiation of pivotal Phase 2a trial for BI-1206 in first-line NSCLC and uveal melanoma, and updated clinical data for BT-001 presented at ESMO 2025.

• Accelerated clinical progress led to earlier-than-expected data readouts and regulatory milestones, including FDA Fast Track and Orphan Drug Designations for BI-1808 and BI-1206.

Financial highlights

• Net sales for Jan–Sep 2025 reached SEK 223–223.5 million, mainly from a USD 20 million royalty rights transaction; Q3 2025 net sales were SEK 3.3 million, down from SEK 12.8 million in Q3 2024.

• Operating costs for Jan–Sep 2025 totaled SEK 446 million, up from SEK 369 million in 2024; Q3 2025 operating costs were SEK 137 million.

• Jan–Sep 2025 loss after tax was SEK -207.1 million, improving from SEK -312.5 million year-over-year; Q3 2025 loss after tax was SEK -129.2 million.

• Liquid funds and investments at period end were SEK 690–690.5 million, supporting operations into Q1 2027.

• Cash flow from operating activities for Jan–Sep 2025 was SEK -157.2 million, improved from SEK -282.2 million prior year.

Outlook and guidance

• Multiple data updates for BI-1808 and BI-1206 expected in H2 2025, including Phase II-A monotherapy and combination data; first data from BI-1206 first-line solid tumor study expected in H2 2026.

• Potential for pivotal studies in 2026 for BI-1808 monotherapy in T cell lymphoma and BI-1206 in non-Hodgkin lymphoma; focus on partnering opportunities as mature data emerges.

• Sufficient funding to reach upcoming value inflection points.